UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 116

Sortiert nach

Roles of cytokines and T cells in the pathogenesis of myasthenia gravis

Clinical and experimental immunology, 2021-03, Vol.203 (3), p.366-374

2021

Volltextzugriff (PDF)

Cardiac involvements in myasthenia gravis associated with anti-Kv1.4 antibodies

European journal of neurology, 2014-02, Vol.21 (2), p.223-230

2014

Volltextzugriff (PDF)

Taste disorders in myasthenia gravis: a multicenter cooperative study

European journal of neurology, 2013-01, Vol.20 (1), p.205-207

2013

Volltextzugriff (PDF)

Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis

Journal of the neurological sciences, 2013-10, Vol.333, p.e432-e433

2013

Volltextzugriff (PDF)

Monitoring treatment with cyclosporine microemulsion in myasthenia gravis

European journal of neurology, 2008-06, Vol.15 (6), p.598-604

2008

Volltextzugriff (PDF)

The importance of follow-up thoracic imaging in myasthenia gravis patients

Journal of the neurological sciences, 2013-10, Vol.333, p.e428-e428

2013

Volltextzugriff (PDF)

FP59-FR-01 Factors associated with response to calcineurin inhibitors in myasthenia gravis

Journal of the neurological sciences, 2009, Vol.285, p.S150-S150

2009

Volltextzugriff (PDF)

Overlooked non-motor symptoms in myasthenia gravis

Journal of Neurology, Neurosurgery and Psychiatry, 2013-09, Vol.84 (9), p.989-994

2013

Volltextzugriff (PDF)

P275 Response to rozanolixizumab in patients with generalized myasthenia gravis (gMG) from the Phase 3 MycarinG study

Neuromuscular disorders : NMD, 2023-10, Vol.33, p.S178-S179

2023

Volltextzugriff (PDF)

Perivascular infiltrate of memory lymphocytes and mature dendritic cells in MG thymomas

Neurology, 2005-09, Vol.65 (5), p.770

2005

Volltextzugriff (PDF)

P276 Long-term safety, and efficacy of subcutaneous Efgartigimod PH20 in patients with generalized myasthenia gravis: interim results of ADAPT-SC

Neuromuscular disorders : NMD, 2023-10, Vol.33, p.S179-S179

2023

Volltextzugriff (PDF)

P273 Long-term safety, efficacy & self-injection satisfaction with zilucoplan in myasthenia gravis: RAISE-XT interim analysis

Neuromuscular disorders : NMD, 2023-10, Vol.33, p.S178-S178

2023

Volltextzugriff (PDF)

P277 Long-term safety, tolerability, and efficacy of Efgartigimod in patients with Generalized Myasthenia Gravis: concluding analyses from the ADAPT+ study

Neuromuscular disorders : NMD, 2023-10, Vol.33, p.S179-S179

2023

Volltextzugriff (PDF)

P.034 Minimal symptom expression following treatment with efgartigimod in patients with Generalized Myasthenia Gravis

Canadian journal of neurological sciences, 2023-06, Vol.50 (s2), p.S67-S67

2023

Volltextzugriff (PDF)

P.044 Efficacy, safety, and tolerability of efgartigimod in AChR-Ab– patients with Generalized Myasthenia Gravis: interim analysis of ADAPT/ADAPT

Canadian journal of neurological sciences, 2023-06, Vol.50 (s2), p.S70-S70

2023

Volltextzugriff (PDF)

P.054 Long-term safety and efficacy of zilucoplan in myasthenia gravis: additional interim analyses of RAISE-XT

Canadian journal of neurological sciences, 2024-06, Vol.51 (s1), p.S30-S31

2024

Volltextzugriff (PDF)

P.043 Long-term safety, tolerability, and efficacy of efgartigimod in patients with Generalized Myasthenia Gravis: concluding analyses from ADAPT

Canadian journal of neurological sciences, 2023-06, Vol.50 (s2), p.S69-S69

2023

Volltextzugriff (PDF)

Open label extension trial of regain to evaluate the safety and efficacy of eculizumab in patients from japan with refractory generalized myasthenia gravis

Journal of the neurological sciences, 2017-10, Vol.381, p.132-133

2017

Volltextzugriff (PDF)

Agraphia and acalculia after a left prefrontal (F1, F2) infarction

Journal of neurology, neurosurgery and psychiatry, 1995-05, Vol.58 (5), p.629-632

1995

Volltextzugriff (PDF)

Early fast-acting treatment strategy against generalized myasthenia gravis

Journal of the neurological sciences, 2017-10, Vol.381, p.1082-1083

2017

Volltextzugriff (PDF)

P.026 Response to eculizumab in patients with myasthenia gravis recently treated with chronic intravenous immunoglobulin

Canadian journal of neurological sciences, 2019-06, Vol.46 (s1), p.S20-S21

2019

Volltextzugriff (PDF)

Sex differences in prognosis and quality of life in myasthenia gravis

Journal of the neurological sciences, 2017-10, Vol.381, p.477-477

2017

Volltextzugriff (PDF)

Social disadvantages associated with myasthenia gravis and its treatment: A multicenter cross-sectional study

Journal of the neurological sciences, 2017-10, Vol.381, p.821-821

2017

Volltextzugriff (PDF)

A.01 Relieving the burden of myasthenia gravis: eculizumab reduces exacerbation, hospitalization and rescue therapy rates

Canadian journal of neurological sciences, 2019-06, Vol.46 (s1), p.S8-S8

2019

Volltextzugriff (PDF)

Cardiac involvements in myasthenia gravis associated with anti‐ K v1.4 antibodies

European journal of neurology, 2014-02, Vol.21 (2), p.223-230

2014

Volltextzugriff (PDF)

1 – 25 von 116

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(98)
Mit Volltextzugriff
(91)

Publikationsform

Sprache

Englisch
(93)
Japanisch
(41)

Erscheinungsjahr

n.n

Thema

Humans
(70)
Life Sciences & Biomedicine
(53)
Science & Technology
(53)
Male
(48)
Female
(45)
Middle Aged
(42)
Adult
(39)
Biological And Medical Sciences
(38)
Neurosciences & Neurology
(37)
Neurosciences
(32)
Aged
(31)
Medical Sciences
(26)
Clinical Neurology
(20)
Myasthenia Gravis
(20)
Neurology
(18)
Aged, 80 And Over
(15)
Fundamental And Applied Biological Sciences. Psychology
(15)
Vertebrates: Nervous System And Sense Organs
(13)
Adolescent
(12)
Molecular Sequence Data
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Roles of cytokines and T cells in the pathogenesis of myasthenia gravis

Cardiac involvements in myasthenia gravis associated with anti-Kv1.4 antibodies

Taste disorders in myasthenia gravis: a multicenter cooperative study

Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis

Monitoring treatment with cyclosporine microemulsion in myasthenia gravis

The importance of follow-up thoracic imaging in myasthenia gravis patients

FP59-FR-01 Factors associated with response to calcineurin inhibitors in myasthenia gravis

Overlooked non-motor symptoms in myasthenia gravis

P275 Response to rozanolixizumab in patients with generalized myasthenia gravis (gMG) from the Phase 3 MycarinG study

Perivascular infiltrate of memory lymphocytes and mature dendritic cells in MG thymomas

P276 Long-term safety, and efficacy of subcutaneous Efgartigimod PH20 in patients with generalized myasthenia gravis: interim results of ADAPT-SC

P273 Long-term safety, efficacy & self-injection satisfaction with zilucoplan in myasthenia gravis: RAISE-XT interim analysis

P277 Long-term safety, tolerability, and efficacy of Efgartigimod in patients with Generalized Myasthenia Gravis: concluding analyses from the ADAPT+ study

P.034 Minimal symptom expression following treatment with efgartigimod in patients with Generalized Myasthenia Gravis

P.044 Efficacy, safety, and tolerability of efgartigimod in AChR-Ab– patients with Generalized Myasthenia Gravis: interim analysis of ADAPT/ADAPT

P.054 Long-term safety and efficacy of zilucoplan in myasthenia gravis: additional interim analyses of RAISE-XT

P.043 Long-term safety, tolerability, and efficacy of efgartigimod in patients with Generalized Myasthenia Gravis: concluding analyses from ADAPT

Open label extension trial of regain to evaluate the safety and efficacy of eculizumab in patients from japan with refractory generalized myasthenia gravis

Agraphia and acalculia after a left prefrontal (F1, F2) infarction

Early fast-acting treatment strategy against generalized myasthenia gravis

P.026 Response to eculizumab in patients with myasthenia gravis recently treated with chronic intravenous immunoglobulin

Sex differences in prognosis and quality of life in myasthenia gravis

Social disadvantages associated with myasthenia gravis and its treatment: A multicenter cross-sectional study

A.01 Relieving the burden of myasthenia gravis: eculizumab reduces exacerbation, hospitalization and rescue therapy rates

Cardiac involvements in myasthenia gravis associated with anti‐ K v1.4 antibodies

Suchergebnisse filtern